Literature DB >> 21584660

Immunohistochemical expression of neuroendocrine secretory protein-55 (NESP-55) in pituitary adenomas.

Mamta Gupta1, Ricardo V Lloyd, Reiner Fischer-Colbrie, Arthur S Tischler, Yogeshwar Dayal.   

Abstract

Neuroendocrine secretory protein-55 (NESP-55) is a recently described member of the chromogranin family and appears to be a marker of the constitutive secretory pathway in certain neural, neuroendocrine, and endocrine cell types. It has been shown to be selectively expressed in tumors differentiating towards the adrenal chromaffin and pancreatic islet cell phenotypes. The highest levels of NESP-55 expression, at least in animals, appear to be in the adrenal medulla and the pituitary gland. However, very little is known about the status of NESP-55 expression in pituitary adenomas. We therefore studied the immunohistochemical profile of NESP-55 expression in a series of 30 well-characterized pituitary adenomas (five each of FSH/LH and ACTH, four GH, three TSH, seven prolactin, and six null cells). All tumors were positive for one or more generic marker(s) (chromogranin A, synaptophysin, neuron-specific enolase) of neuroendocrine differentiation. All pituitary adenomas selected for study were stained for NESP-55 with appropriate positive and negative controls. NESP-55 immunoreactivity, seen as brown finely granular cytoplasmic staining of the tumor cells with prominent perinuclear accentuation, was graded as focal (<10% tumor cells staining), moderate (10-50% tumor cells staining), and diffuse (>50% tumor cell staining). Four of seven prolactinomas were positive for NESP-55 (one focal, two moderate, and one diffuse). Two of four GH adenomas were also positive (one focal and one diffuse) while only 1/5 FSH tumors showed a moderately intense immunoreactivity. All other pituitary adenomas were completely negative for NESP-55. Our results indicate that, in human pituitary adenomas, NESP-55 has a more restricted pattern of expression than that of chromogranins A and B. Since immunohistochemical expression of NESP-55 is largely confined to prolactinomas and GH adenomas, it raises the possibility that NESP-55 may somehow be involved in the secretory pathways of these specific cell types.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21584660     DOI: 10.1007/s12022-011-9162-y

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  34 in total

1.  Secretion and molecular forms of NESP55, a novel genomically imprinted neuroendocrine-specific protein from AtT-20 cells.

Authors:  Susanne Eder; Johannes Leierer; Lars Klimaschewski; Alexander Wilhelm; Walter Volknandt; Andrea Laslop; Reiner Fischer-Colbrie
Journal:  Neurosignals       Date:  2004 Nov-Dec

2.  Bidirectional imprinting of a single gene: GNAS1 encodes maternally, paternally, and biallelically derived proteins.

Authors:  B E Hayward; V Moran; L Strain; D T Bonthron
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

3.  Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion.

Authors:  K Tatemoto; S Efendić; V Mutt; G Makk; G J Feistner; J D Barchas
Journal:  Nature       Date:  1986 Dec 4-10       Impact factor: 49.962

4.  Secretoneurin releases dopamine from rat striatal slices: a biological effect of a peptide derived from secretogranin II (chromogranin C).

Authors:  A Saria; J Troger; R Kirchmair; R Fischer-Colbrie; R Hogue-Angeletti; H Winkler
Journal:  Neuroscience       Date:  1993-05       Impact factor: 3.590

5.  Deletion of the NESP55 differentially methylated region causes loss of maternal GNAS imprints and pseudohypoparathyroidism type Ib.

Authors:  Murat Bastepe; Leopold F Fröhlich; Agnès Linglart; Hilal S Abu-Zahra; Katsuyoshi Tojo; Leanne M Ward; Harald Jüppner
Journal:  Nat Genet       Date:  2004-12-12       Impact factor: 38.330

6.  Differentiation of human pituitary adenomas determines the pattern of chromogranin/secretogranin messenger ribonucleic acid expression.

Authors:  L Jin; W F Chandler; J B Smart; B G England; R V Lloyd
Journal:  J Clin Endocrinol Metab       Date:  1993-03       Impact factor: 5.958

7.  Immunohistochemical detection of secretoneurin, a novel neuropeptide endoproteolytically processed from secretogranin II, in normal human endocrine and neuronal tissues.

Authors:  K W Schmid; B Kunk; R Kirchmair; M Tötsch; W Böcker; R Fischer-Colbrie
Journal:  Histochem J       Date:  1995-06

Review 8.  The chromogranins: their roles in secretion from neuroendocrine cells and as markers for neuroendocrine neoplasia.

Authors:  Steven A Feldman; Lee E Eiden
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

9.  7B2, a new protein secreted by human functionless pituitary tumours, in vitro.

Authors:  M S Venetikou; M A Ghatei; J M Burrin; S Latif; S R Bloom
Journal:  Acta Endocrinol (Copenh)       Date:  1988-08

Review 10.  The chromogranins A and B: the first 25 years and future perspectives.

Authors:  H Winkler; R Fischer-Colbrie
Journal:  Neuroscience       Date:  1992-08       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.